Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Antonio Jimeno-Largo

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-2478
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOM-MED
    DivisionONC GENERAL OPERATIONS


    Collapse Research 
    Collapse research activities and funding
    P50CA261605     (JIMENO, ANTONIO)Sep 1, 2021 - Aug 31, 2026
    NIH
    Colorado Head and Neck Cancer SPORE
    Role: Principal Investigator
    R01DE030683     (JIMENO, ANTONIO)Apr 1, 2021 - Mar 31, 2026
    NIH
    Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
    Role: Principal Investigator
    T32CA236734     (JIMENO, ANTONIO)Jul 8, 2019 - Jun 30, 2030
    NIH
    Cancer Immunotherapy and Experimental Therapeutics - T32
    Role: Principal Investigator
    R01CA213102     (JIMENO, ANTONIO)Aug 1, 2017 - Jul 31, 2021
    NIH
    Development of an autologous humanized model of melanoma exploring human thymic education capacity
    Role: Principal Investigator
    R01DE024371     (WANG, XIAO-JING)Aug 1, 2014 - Jul 31, 2019
    NIH
    Identifying oral cancer stem cell properties affected by the microenvironment
    Role: Co-Principal Investigator
    R56DE023245     (REYLAND, MARY ELAINE)Sep 26, 2012 - Aug 31, 2015
    NIH
    Functional characterization of salivary gland cancers and development of patient
    Role: Co-Principal Investigator
    R21CA156114     (JIMENO, ANTONIO)Sep 8, 2011 - Aug 31, 2014
    NIH
    Rational combination of EGFR and Hedgehog inhibitors in head and neck cancer
    Role: Principal Investigator
    R01CA149456     (JIMENO, ANTONIO)Aug 9, 2010 - May 31, 2022
    NIH
    Characterizing the regulation of PD-1 ligands in head and neck cancer stem cells using an autologous humanized model with T cell education capability
    Role: Principal Investigator
    R21DE019712     (JIMENO, ANTONIO)Sep 1, 2009 - Aug 31, 2012
    NIH
    Rational generation of a head and neck squamous cell cancer direct xenograft mode
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jimeno A, Baranda J, Iams WT, Park JC, Mita M, Gordon MS, Taylor M, Dhani N, Leal AD, Neupane P, Eng C, Yeku O, Mita A, Moser JC, Butler M, Loughhead SM, Jennings J, Miselis NR, Ji RR, Nair N, Kornacker M, Zwirtes RF, Bernstein H, Sharei A. Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. Invest New Drugs. 2023 04; 41(2):284-295. PMID: 36867316.
      View in: PubMed
    2. Ramos SA, Morton JJ, Yadav P, Reed B, Alizadeh SI, Shilleh AH, Perrenoud L, Jaggers J, Kappler J, Jimeno A, Russ HA. Generation of functional human thymic cells from induced pluripotent stem cells. J Allergy Clin Immunol. 2022 02; 149(2):767-781.e6. PMID: 34331993.
      View in: PubMed
    3. Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, Goff LW, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Faulkner R, Eckhardt SG, Adjei AA, Jimeno A. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. Cancer Chemother Pharmacol. 2021 06; 87(6):779-788. PMID: 33634324.
      View in: PubMed
    4. Alzofon N, Jimeno A. Capmatinib for non-small cell lung cancer. Drugs Today (Barc). 2021 Jan; 57(1):17-25. PMID: 33594387.
      View in: PubMed
    5. Morton JJ, Alzofon N, Keysar SB, Chimed TS, Reisinger J, Perrenoud L, Le PN, Nieto C, Gomez K, Miller B, Yeager R, Gao D, Tan AC, Somerset H, Medina T, Wang XJ, Wang JH, Robinson W, Roop DR, Gonzalez R, Jimeno A. Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. Mol Cancer Res. 2021 02; 19(2):346-357. PMID: 33087417.
      View in: PubMed
    6. Alzofon N, Jimeno A. Avapritinib for metastatic or unresectable gastrointestinal stromal tumors. Drugs Today (Barc). 2020 Sep; 56(9):561-571. PMID: 33025950.
      View in: PubMed
    7. Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, Le PN, Nieto C, Chowdhury FN, Tyagi A, Lyons TR, Young CD, Zhou H, Somerset HL, Wang XJ, Jimeno A. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells. Cancer Res. 2020 10 01; 80(19):4185-4198. PMID: 32816856.
      View in: PubMed
    8. Marsh S, Jimeno A. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors. Drugs Today (Barc). 2020 Jun; 56(6):377-387. PMID: 32525136.
      View in: PubMed
    9. Amaya ML, Jimeno A, Kamdar M. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Drugs Today (Barc). 2020 Apr; 56(4):287-294. PMID: 32309823.
      View in: PubMed
    Jimeno-Largo's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (77) concept(s)
    _
    Co-Authors Expand Description
    See all (14) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)